Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders

被引：80

作者：

McClure, R ^{[1
]}

Mai, M

Lasho, T

机构：

[1] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Hematol Res, Rochester, MN USA

来源：

LEUKEMIA | 2006年 / 20卷 / 01期

关键词：

D O I：

10.1038/sj.leu.2404007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：168 / 171

页数：5

共 8 条

[1] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[2] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].

James, C ;

Ugo, V ;

Le Couédic, JP ;

Staerk, J ;

Delhommeau, F ;

Lacout, C ;

Garçon, L ;

Raslova, H ;

Berger, R ;

Bennaceur-Griscelli, A ;

Villeval, JL ;

Constantinescu, SN ;

Casadevall, N ;

Vainchenker, W .

NATURE, 2005, 434 (7037) :1144-1148

[3]

JELINEK J, 2005, BLOOD 0721

[4] Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders [J].

Jones, AV ;

Kreil, S ;

Zoi, K ;

Waghorn, K ;

Curtis, C ;

Zhang, LY ;

Score, J ;

Seear, R ;

Chase, AJ ;

Grand, FH ;

White, H ;

Zoi, C ;

Loukopoulos, D ;

Terpos, E ;

Vervessou, EC ;

Schultheis, B ;

Emig, M ;

Ernst, T ;

Lengfelder, E ;

Hehlmann, R ;

Hochhaus, A ;

Oscier, D ;

Silver, RT ;

Reiter, A ;

Cross, NCP .

BLOOD, 2005, 106 (06) :2162-2168

[5] A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].

Kralovics, R ;

Passamonti, F ;

Buser, AS ;

Teo, S ;

Tiedt, R ;

Passweg, JR ;

Tichelli, A ;

Cazzola, M ;

Skoda, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790

[6] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].

Levine, RL ;

Wadleigh, M ;

Cools, J ;

Ebert, BL ;

Wernig, G ;

Huntly, BJP ;

Boggon, TJ ;

Wlodarska, L ;

Clark, JJ ;

Moore, S ;

Adelsperger, J ;

Koo, S ;

Lee, JC ;

Gabriel, S ;

Mercher, T ;

D'Andrea, A ;

Fröhling, S ;

Döhner, K ;

Marynen, P ;

Vandenberghe, P ;

Mesa, RA ;

Tefferi, A ;

Griffin, JD ;

Eck, MJ ;

Sellers, WR ;

Meyerson, M ;

Golub, TR ;

Lee, SJ ;

Gilliland, DG .

CANCER CELL, 2005, 7 (04) :387-397

[7]

LEVINE RL, 2005, BLOOD 0804

[8] The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes [J].

Steensma, DP ;

Dewald, GW ;

Lasho, TL ;

Powell, HL ;

McClure, RF ;

Levine, RL ;

Gilliland, DG ;

Tefferi, A .

BLOOD, 2005, 106 (04) :1207-1209

← 1 →